Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STLX-2012 SAD Study in Healthy Volunteers
NCT07231744Phase 1Not yet recruiting
- Sponsor
- Stelexis Therapeutics
- Start
- Oct 2026
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing STLX-2012 with Placebo (2 arms). Primary endpoint: Incidence and severity of Adverse Events at 56 days. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
STLX-2012
Beyond the preview
Go deeper on NCT07231744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07231744.